1-5 of 5
Begoña Jimenez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P5-12-03: Influence of antibiotic use on the efficacy of neoadjuvant chemotherapy in breast cancer

Free
Manuel Zalabardo Aguilar, Inés Fernández Sánchez, Alberto Girona Torres, Álvaro González Ortiz, José Manuel Jerez Aragonés, Alfonso Sánchez Muñoz, Javier Pascual López, María José Bermejo Pérez, Antonia Márquez Aragonés, Bella Pajares Hachero, Francisco Carabantes Ocón, Begoña Jiménez Rodríguez, María Emilia Domínguez Recio, Ana Godoy Ortiz, Tamara Díaz Redondo, Ester Villar Chamorro, Marcos Iglesias Campos, Irene Zarcos Pedrinaci, Nuria Ribelles Entrena, Emilio Alba Conejo
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P5-12-03.
https://doi.org/10.1158/1557-3265.SABCS24-P5-12-03
Published: 13 June 2025
View articletitled, Abstract P5-12-03: Influence of antibiotic use on the efficacy of neoadjuvant chemotherapy in breast cancer
Journal Articles

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

Free
Aleix Prat, Ana Lluch, Arran K. Turnbull, Anita K. Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, José Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montserrat Muñoz, Laia Paré, Joel S. Parker, Nuria Ribelles, Begoña Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva Carrasco, Miguel Martín, J. Michael Dixon, Charles M. Perou, Emilio Alba
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (12): 3035–3044.
https://doi.org/10.1158/1078-0432.CCR-16-2092
Published: 14 June 2017
View articletitled, A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse
Open the PDF for A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse in another window
Includes: Supplementary data
Journal Articles

Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?

Free
Desamparados Roda, Begoña Jimenez, Udai Banerji
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (9): 2127–2132.
https://doi.org/10.1158/1078-0432.CCR-15-1855
Published: 01 May 2016
View articletitled, Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
Open the PDF for Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic? in another window
Includes: Supplementary data
Journal Articles

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

Free
Aleix Prat, Patricia Galván, Begoña Jimenez, Wesley Buckingham, H. Arthur Jeiranian, Carl Schaper, Maria Vidal, Martina Álvarez, Sherley Díaz, Catherine Ellis, Paolo Nuciforo, Sean Ferree, Nuria Ribelles, Barbara Adamo, Santiago Ramón y Cajal, Vicente Peg, Emilio Alba
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (3): 560–566.
https://doi.org/10.1158/1078-0432.CCR-15-0630
Published: 31 January 2016
View articletitled, Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
Open the PDF for Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay in another window
Includes: Supplementary data
Journal Articles

Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Free
Saeed Rafii, Desamparados Roda, Elena Geuna, Begona Jimenez, Karim Rihawi, Marta Capelan, Timothy A. Yap, L. Rhoda Molife, Stanley B. Kaye, Johann S. de Bono, Udai Banerji
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (8): 1869–1876.
https://doi.org/10.1158/1078-0432.CCR-14-2424
Published: 14 April 2015
View articletitled, Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials
Open the PDF for Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials in another window
Includes: Supplementary data